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Introduction
In addition to structural and enzymatic proteins essential 
for virus replication, the HIV-1 genome encodes six regulatory 
proteins (Tat, Rev, Nef, Vif, Vpr, and Vpu) that modulate virus 
fitness and infectivity in vivo. Among these proteins, Vif (Viral 
Infectivity Factor), a highly basic protein of 23 kDa, has been 
shown to be essential for viral pathogenesis by allowing HIV-1 
replication in non-permissive cells, such as CD4+ T lymphocytes 
and macrophages, the natural cell targets of the virus. In those 
cells, Vif neutralizes the cellular anti-HIV defense by interacting 
with cellular cytosine deaminases APOBEC3G (APOlipoprotein 
B mRNA-Editing enzyme-Catalytic, polypeptide-like 3G, or 
A3G) and A3F and inhibiting their antiviral activities.1 In the 
absence of a functional Vif, A3G/3F proteins deaminate cytidines 
into uridines in the minus strand DNA2-4 and inhibit reverse 
transcription and integration through deaminase-independent 
mechanisms.5 Vif counteracts A3G/3F and allows HIV-1 repli-
cation by hijacking several cellular processes. First, Vif targets 
A3G/3F for degradation via the proteasome by recruiting an E3 
ubiquitin ligase cellular complex composed of Elongin B (EloB), 
Elongin C (EloC), Cullin 5 (Cul5), and RING-box protein 2 
(Rbx2).6-8 CBF-β, the transcriptional Core Binding Factor-β, 
has recently been shown to be an integral component of this com-
plex, directly interacting with Vif and favoring the specific poly-
ubiquitination and degradation of A3G.9-11 Second, Vif regulates 
A3G translation by binding to the 5′-UTR (untranslated region) 
of its mRNA, thus likely preventing its scanning by the ribo-
some.12 These two mechanisms seem to be independent pathways 
utilized by Vif to reduce A3G expression,13,14 and to indirectly 
interfere with its packaging.15 In addition, Vif has been proposed 
to promote the assembly of A3G into presumably packaging-
incompetent high molecular mass complexes.16
Vif consists of several functional and conserved domains 
(Fig. 1) (for reviews see refs. 17 and 18). The N-terminal domain 
(NTD) of Vif (residues 1–100) is enriched in hydrophobic amino 
acids, notably in conserved tryptophan residues. Mutagenesis 
studies have shown that these residues and other motifs/sequences 
are important for binding to A3G/3F,19-22 but also to A3H, A3C, 
and A3DE.23-25 In particular, NTD residues W11, Y30, and Y40 
are important for Vif binding to RNA in vitro26 and in infected 
cells.27 Moreover, residues W21 and W38 are involved in binding 
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The viral infectivity factor (Vif) is essential for the productive infection and dissemination of hIV-1 in non-permissive 
cells, containing the cellular anti-hIV defense cytosine deaminases APOBec3 (A3G and A3F). Vif neutralizes the antiviral 
activities of the APOBec3G/F by diverse mechanisms including their degradation through the ubiquitin/proteasome 
pathway and their translational inhibition. In addition, Vif appears to be an active partner of the late steps of viral repli-
cation by interacting with Pr55Gag, reverse transcriptase and genomic RNA. here, we expressed and purified full-length 
and truncated Vif proteins, and analyzed their RNA binding and chaperone properties. First, we showed by cD and NMR 
spectroscopies that the N-terminal domain of Vif is highly structured in solution, whereas the c-terminal domain remains 
mainly unfolded. Both domains exhibited substantial RNA binding capacities with dissociation constants in the nano-
molar range, whereas the basic unfolded c-terminal domain of Vif was responsible in part for its RNA chaperone activity. 
second, we showed by NMR chemical shift mapping that Vif and Ncp7 share the same binding sites on tRNALys3, the 
primer of hIV-1 reverse transcriptase. Finally, our results indicate that Vif has potent RNA chaperone activity and provide 
direct evidence for an important role of the unstructured c-terminal domain of Vif in this capacity.
www.landesbioscience.com RNA Biology 907
to CBF-β.9,10,28 The central domain (residues 108–139) consti-
tutes a non-consensus HCCH zinc-binding motif that binds 
Cul5.29,30 Finally, the C-terminal domain (CTD) consists of 
(1) a SOCS-box motif (144SLQ[Y/F]LAL150) that promotes the 
interaction with EloC/EloB,31 and is therefore important for the 
recruitment of the E3 ubiquitin ligase that targets A3G for degra-
dation32; (2) an oligomerization domain (residues 151–164) con-
taining a 161PPLP164 motif critical for Vif oligomerization33,34 and 
its interaction with the cellular kinase Hck34,35; and (3) a domain 
(residues 172–192) important for binding with Pr55Gag,36,37 mem-
branes,38 and reverse transcriptase.39
Very recently, the structure of Vif in complex with CBF-β, 
Cul5 and EloB/C proteins was solved by X-ray crystallography.40 
The structure of Vif in the complex is maintained by extensive 
interactions with CBF-β, which binds to hydrophobic residues of 
Vif, leaving the positively charged surface exposed. In addition, 
Vif also interacts with Cul5 and EloC through two helices belong-
ing respectively to the HCCH and BC-box domains. Although 
this structure explains how Vif can hijack the cellular protea-
some degradation pathway, information on Vif interaction with 
APOBEC3 proteins and RNAs is still lacking. Alone in solution, 
Vif has been shown to be structurally unfolded,41-43 and the dis-
ordered nature of the CTD is in line with secondary structure 
prediction models.44 Moreover, conformational refolding of Vif 
has been observed upon self-oligomerization,41 binding to EloC45 
and to specific RNA motifs such as the Trans-acting Responsive 
(TAR) element,46,47 confirming the importance of unstructured 
regions in the multifunctional properties of Vif. Beside, direct 
analyses of Vif in cell by fluorescence techniques revealed the 
oligomerization of Vif through the C-terminal domain and the 
perturbation of this intrinsic property when Vif encounters bind-
ing partners such as APOBEC3G or Hck proteins.18,48
Vif has previously been shown to be an RNA binding protein 
with preferential binding to short RNA motifs present in the 5′ 
region of HIV-1 genomic RNA46,49,50 as well as to A3G mRNA.12,47 
Moreover, Vif seems to participate to several important steps of 
the viral replication cycle such as reverse transcription,51,52 and 
HIV-1 genomic RNA dimerization thanks to its RNA chaper-
one activity.18,52 The basic and intrinsically disordered nature of 
HIV-1 Vif protein may account for its ability to interact with 
several other proteins and nucleic acids in a manner similar to 
RNA chaperones such as HIV-1 NCp753 and Tat48 proteins or 
Figure 1. hIV-1 Vif and its domains. (A) schematic representation of hIV-1 Vif functional domains and Vif constructions studied in this paper. hIV-1 Vif 
contains several functional domains, including an RNA/APOBec3 binding domain, a conserved zinc-binding hydrophobic hcch motif and a down-
stream sOcs-box, a multimerization domain (M) and a Gag/membrane binding domain. The number in parenthesis corresponds to the number of Vif 
amino acids encompassed in each construction. (B) sDs-PAGe analysis (14%) of purified Vif and its domains, on the left analysis of NiNTA purification 
of Vif (95–192) in denaturing condition, AL: after lysis of bacteria by denaturing lysis buffer, FT: analysis of the flow-through, Vif (95–192): analysis of the 
fractions of the NiNTA elution containing Vif (95–192) (see materials and methods). On the right, analysis of the other purified proteins studied in this 
paper. Proteins were visualized by coomassie blue staining. 
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Figure 1. hIV-1 Vif and its domains. (C) Dynamic light scattering profiles of the hIV-1 Vif protein and its domains, Vif (1–150), Vif (1–97), Vif (95–192). The 
average hydrodynamic radius is indicated for each Vif protein domain. (D) 1h-15N TROsY NMR spectrum of Vif (95–192). The spectrum was recorded at 
20 °c in the protein buffer.
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the cellular fragile X mental retardation protein FMRP.54 In this 
respect, the NTD of Vif was previously described to be respon-
sible for its specific RNA binding affinity whereas the CTD, 
from residue 156 to 192, which contains many positively charged 
residues, could contribute to non-specific RNA binding.26 To 
examine this possibility, we purified full-length and individual 
N- and C-terminal domains of HIV-1 Vif protein and analyzed 
their nucleic acid binding activities for a panel of RNAs. We also 
determined their oligomerization state and secondary structure 
elements in vitro. Moreover, we showed by NMR chemical shift 
mapping that Vif and NCp7 share the same binding sites on 
tRNALys
3
, with a joined participation of the NTD and CTD of 
Vif. Finally, we observed that Vif acts as chaperone by promoting 
efficient RNA annealing. Importantly our results provided direct 
evidence for an important role of the unstructured CTD of Vif 
in this capacity.
Results
Rational design of HIV-1 Vif domains and their purification
The subdomains of HIV-1 Vif protein (HXB2 isolate) stud-
ied in this work (Fig. 1A) were defined considering functional 
domains of Vif, solution conformation and dynamics of Vif 
obtained by mass spectrometry (MS),42 NMR data on the CTD 
of Vif,43 biochemical data regarding intrinsic proteolysis of Vif55,56 
and disorder prediction using various software tools.
First, it was shown that the NTD of Vif (residues 1–86) dis-
played the most protected region against amide exchange.42,45 
Consequently, this region is likely the most structured, in agree-
ment with disorder prediction. Notably, the NTD of Vif contains 
a tryptophan-rich region that likely gives the protein the prop-
erty to bind RNA.26,46,50 Second, the CTD of Vif is predicted 
to be disordered, and this feature was actually demonstrated in 
solution by NMR and MS, either alone or in a full-length pro-
tein.42,43 This domain includes the SOCS-box, the multimeriza-
tion PPLP motif and the Pr55Gag/membrane binding domain. 
Third, it has been noticed that Vif contains a specific cleavage 
site for the HIV-1 protease after residue 150, releasing a natural 
1–150 degradation intermediate that is found not only in virions, 
but also in cells, and could thus reflect a co-packaging of this 
truncated form.55,56 We did not study the corresponding peptide 
Vif (151–192) as we did not see any noticeable effects of this pep-
tide on various HIV-1 replication steps (JC Paillart, unpublished 
results). We thus decided to work with three truncated version of 
Vif, namely Vif (1–97) ending up just after a predicted β-sheet 
secondary structure,17 Vif (95–192) and Vif (1–150) and to com-
pare their RNA binding and chaperone properties to that of full-
length Vif protein.
Vif and its domains were overproduced in E. coli and purified 
in denaturing conditions as previously described.42,44,46,47,50,52,57,58 
It is known that recombinant Vif expressed alone in E. coli local-
izes to insoluble inclusion bodies. Vif in inclusion bodies can 
be isolated under denaturating conditions, purified by Ni-NTA 
affinity chromatography, and then refolded by subsequent dialy-
sis with buffers containing decreasing concentrations of denatur-
ant. The renaturing conditions for each domain were adjusted to 
optimize their solubility. A final concentration of 40 µmol/L for 
Vif (1–97) and Vif (95–192) and of 10 µmol/L for Vif and Vif 
(1–150) were obtained. The analysis by SDS-PAGE gel electro-
phoresis of purified Vif and its domains is shown in Figure 1B.
Vif has been shown to self-associate both in vitro33,41,59 and 
in vivo.18,34 We thus focused our analysis on the characterization 
of Vif domains regarding their capacity to self-assemble, their 
secondary structure, together with their RNA binding and chap-
erone activities.
Biophysical analyses of HIV-1 Vif domains (NTD and 
CTD)
In a first set of experiments, samples of full-length Vif and of 
its truncated versions were used to analyze (1) their homogeneity 
by dynamic light scattering (DLS), (2) their secondary structure 
by circular dichroïsm (CD), and (3) their amenability to struc-
tural studies by NMR.
DLS was essential to assess the quality of protein samples 
before further experiments. We found that distributions of all 
Vif proteins appeared unimodal, and thus we could exclude 
disordered aggregation in our protein samples. The estimated 
polydispersity degree, which is indicative of the oligomeriza-
tion modes of the protein, was between 30 to 40% (Fig. 1C). A 
mean hydrodynamic radius of 7.5 nm was measured for Vif in 
good agreement with previous studies.46,47,49 For Vif domains, the 
hydrodynamic radii were slightly lower, varying from 4 to 5 nm 
(Fig. 1C), suggesting that Vif (1–150) and Vif (1–97) may also 
form multimers despite the absence of the 161PPLP164 oligomeriza-
tion motif. This is not surprising as domains outside this motif 
have been shown to contribute to multimerization.34,47 Moreover, 
the 161PPLP164 domain is not conserved among HIV-2 and SIV,17 
confirming that other unknown domains may be involved in 
oligomerization.
The secondary structure of Vif and its domains were further 
investigated using far-UV CD (Table 1). CD spectra in the far-
UV domain (180–260 nm) give information on the secondary 
structure of proteins, namely their content in α-helix, β-strands, 
and random secondary structures. In good agreement with previ-
ous studies,46,47,49 wild-type Vif is composed of 15% of α-helix, 
Table 1. Analysis of cD spectra of Vif and its domains
Secondary structure
Proteins





























The data were fit using K2D software http://www.embl.de/~andrade/k2d.
html.86 Number in parenthesis shows the percentage of the secondary 
structure predictions by PsIPReD http://bioinf.cs.ucl.ac.uk/psipred/ calcu-
lated for each protein from the hIV-1 Vif protein prediction of its secondary 
structure.
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33% of β-strands and 52% of disordered regions. As expected 
from secondary structure prediction,17 Vif (1–150) and Vif 
(1–97) show an overall structured organization, while Vif (95–
192) is much less structured with only 35% of secondary struc-
tures (α-helix + β-strands). The sum of secondary structures 
predicted and observed by CD are very similar (Table 1), even 
if differences exist in the repartition of the secondary structures. 
It is possible that due to the great diversity of topologies found 
within proteins, the limited representation of secondary struc-
tural components within the CD reference databases provides a 
less accurate determination.60 However, altogether our data point 
out that the percentage of random structures is smaller for Vif 
(1–150) and Vif (1–97), where the CTD is missing. Vif (1–97) 
presents the highest percentage of secondary structures (68%). 
This domain could have been amenable to structural study by 
NMR or X-ray crystallography. Unfortunately, its poor solubility 
prevented us from solving its 3D structure. We thus observed 
that the CTD of Vif is disordered in solution, while the NTD is 
the most structured region. Accordingly to the high percentage 
of random regions, the CD signal in the near-UV region, which 
is potentially informative about proteins tertiary structure, was 
nearly zero for all proteins tested.
We then studied the 1D 1H NMR spectrum of Vif and its 
domains (Fig. S1). Taking into account that Vif forms multim-
ers in solution, the poor dispersion of NMR signals in the amide 
region (7.5–10 ppm) indicated that the observable protons are not 
Figure 2. Fluorescence titrations of Vif and its domains with RNA at 25 °c. (A) Vif/tRNALys3, (B) Vif (1–150)/ tRNA
Lys
3, (C) Vif (1–97)/ tRNA
Lys
3, (D) Vif (95–192) 
tRNALys3, (E) Vif (95–192)/short RNAB and (F) Vif (95–192)/TAR. The dissociation constants (KD) are indicated in nM with the 95% confidence interval 
between parentheses. The maximal fluorescence quenching (Qmax) obtained for each titration is indicated as a percentage (%). The measurements were 
performed in a TRIs-hcl (30 mM, ph 7.5) buffer containing 200 mM Nacl and 10 mM Mgcl2.
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involved in the hydrophobic core of the proteins, but belong to 
a less folded domain. This feature is confirmed by the observa-
tion that the 1D 1H NMR spectrum of Vif and Vif (95–192) are 
identical. Therefore, the only observable part of the Vif protein 
by NMR is its CTD. We subsequently labeled Vif (95–192) by 
15N-nitrogen to analyze this domain by 2D NMR spectroscopy 
(Fig. 1D). Amide group signals were poorly dispersed in the pro-
ton dimension (0.5 ppm) and covered 10 ppm in the nitrogen 
dimension. The signal at 10.07 ppm corresponds to the indol NH 
of the unique tryptophan (W174) present in Vif (95–192). This 
proton signal is also observable in Vif spectrum while the other 
six tryptophan (W5, W11, W21, W38, W70, W79) indol pro-
tons remained unobservable. The poor dispersion of the amide 
groups and the linewidth of the NMR signals of Vif (95–192) 
confirmed that this protein is not structured and forms multim-
ers. The addition of zinc ions did not allow further structuration, 
but an additional broadening of signals was observed. Regarding 
Vif (1–97), very few large signals are observed, indicating that 
this protein forms high molecular weight complex with a low per-
centage of unstructured regions.
Altogether, these biophysical analyses show that Vif NTD is 
highly structured, while the CTD is globally unfolded. These 
results reinforce the data in the literature suggesting that no inter-
action is expected between the N- and the C-terminal domains 
of Vif.41,42,45
The N- and C-terminal domains of HIV-1 Vif have both 
RNA binding capacity
According to rigorous analysis of binding parameters, it was 
previously shown that HIV-1 genomic RNA and A3G mRNA 
contain specific Vif binding sites.12,46,47,49,50 Namely in the 5′-end 
of HIV-1 genomic RNA, Vif binds to the TAR, poly(A), SL1, 
and a short sequence within the Gag coding region (nucleotides 
539–546).50 In line with this study, we focused our attention 
on RNA B (500 nucleotide long RNA encompassing sequence 
499–996 of HIV-1 genomic RNA) and on a shorter version of 
this RNA (sRNA B, nucleotides 499–800), which also contains 
a high affinity binding site for Vif.46 We also investigated the 
interaction of Vif domains with the apical part of TAR (16 nts) 
corresponding to a minimal binding site for Vif (54), and to 
tRNALys
3
 (76 nts), which acts as a primer for HIV-1 reverse tran-
scription. Indeed, Vif has previously been shown to promote the 
annealing of tRNALys
3
 to the PBS (Primer Binding Site), and also 
to inhibit in vitro the NCp7-mediated tRNALys
3
 annealing when 
both proteins are present.52 As no data on the putative interaction 
between Vif and tRNALys
3
 are available, we investigated whether 
Vif is able to bind tRNALys
3
 by fluorescence and NMR spectros-
copies. Actually, 15N-labeled tRNALys
3
 and NMR assignment of 
its imino groups were already available in our group,18,61 thereby 
allowing the use of NMR to study Vif binding to tRNALys
3
. To 
perform N15-labeling, we used a recombinant tRNALys
3
 produced 
in E. coli and functional for the initiation of HIV-1 reverse tran-
scription.62 This recombinant tRNA does not bear all the post-
transcriptional modifications carried by the human tRNALys
3
 but 
we assume that, as for NCp7,63 post-transcriptional modifications 
are not a driving force for the interaction with Vif.
To gain insights into interactions occurring between Vif 
protein domains and a panel of RNAs, we used f luorescence 
spectroscopy. Indeed, Vif contains 8 tryptophans that confer a 
high intrinsic f luorescence signal to the protein. Similarly, Vif 
(1–97) and Vif (1–150) have 7 tryptophan residues, while Vif 
(95–192) possesses only one. Because of their photophysical 
properties and their high sensitivity, tryptophans constitute a 
useful tool to determine binding parameters in protein-nucleic 
acids systems. Upon RNA binding, the f luorescence of Vif and 
its domains were attenuated (Fig. 2), and titration curves rep-
resenting f luorescence quenching were appropriately fitted to 
determine dissociation constants (K
D
). Titration curves of Vif 
proteins with tRNALys
3
 are presented in Figure 2, and the stoe-
chiometry of the different structural domains of Vif in interac-
tion with various RNAs is about one multimer per RNA (data 
not shown). Table 2 summarized the obtained K
D
 values (see 
Materials and Methods). Dissociation constant analysis showed 
that Vif (1–97), which contains the RNA binding domain 
(residues 1–60), binds to all the RNAs tested with constants 
similar to full-length Vif (Table 2). Globally, the K
D
 magni-
tudes range from 10 to 34 nM, corresponding to a high bind-
ing affinity. We also showed that Vif (1–150) binds RNA less 
efficiently (Table 2), and corresponding K
D
 values range from 
30 to 51 nM. This result indicates that the HCCH and SOCS-
box domains do not participate to RNA binding, in agree-
ment with previous results showing that no interaction could 
be observed between a peptide containing the HCCH motif 
and nucleic acids (J-C Paillart, unpublished data). More sur-
prisingly, our data also show that Vif (95–192) strongly binds 
RNAs, with relative dissociation constants ranging from 16 to 
26 nM (Fig. 2; Table 2). The K
D
 of Vif (95–192) for RNA is 
globally lower (or equal) than what observed in the case of Vif 
(1–97) for the same target (Table 2).
Our data also demonstrate for the first time that Vif, as 
NCp7, binds tRNALys
3
 with high affinity (K
D
 = 23 nM) and the 
corresponding dissociation constant is comparable to the one 
determined for NCp7 (K
D
 = 20 nM) at the same MgCl
2
 concen-
tration (Table 2).63 The different domains of Vif also exhibited 
Table 2. Dissociation constants (KD) derived from fluorescence titrations













































each KD value is the average of five titrations, the mean standard deviation 
and the maximal attenuation Qmax are indicated.
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rather good affinity for small and highly structured RNAs such 
as TAR and tRNALys
3
 with very similar K
D
 values (Table 2). 
Interestingly, the comparison of K
D
 values obtained for RNA B 
and sRNA B leads to the observation that highly specific Vif 
binding sites are present in sRNA B (Table 2), confirming the 
presence of Vif preferential binding sites in this region of HIV-1 
genomic RNA.46 It is possible that these high affinity binding 
sites are somehow buried in the complete RNA B, while they are 
exposed in its shorter form and thus available to interact with 
Vif. Alternatively, in the case of RNA B, there could be addi-




Our previous analysis on Vif interaction with various viral 
nucleic acids46 showed that Vif specifically binds some DNA 
and RNA sequences. However, similarly to NCp7,63 the highly 
basic character of Vif promotes its interaction with nucleic acids. 
Indeed, non-specific binding could be revealed through maximal 
fluorescence quenching (Q
max
) values during titration. Globally, 
for non-specific binding, i.e., binding essentially driven by elec-
trostatic interaction due to the highly basic character of Vif, Q
max
 
ranges only from 20 to 40%. On the contrary, it reaches 60 
to 70% for specific binding. Fluorescence titrations of Vif, Vif 
(1–97), and Vif (95–192) were also performed with a previously 
defined “non-specific RNA binder” of Vif, corresponding to a 
repetition of 10 cytosines (C10).46 We thus showed that although 
Vif and its domains bind C10 with a dissociation constant around 
40 nM, the relative Q
max
 values only reach 35%. We also tested 
the interaction of Vif with an E. coli tRNA extract. Noticeably, 
Figure 3. NMR chemical shift mapping of the binding sites of Vif proteins on tRNALys3. (A) Two NMR spectra (2D 
1h-15N TROsY) acquired at 20 °c are 
superimposed: in black for tRNALys3 alone (reference spectrum) and in red for tRNA
Lys
3/Vif complex. (B) The NMR chemical shift mapping is reported on 
the secondary structure of tRNALys3 with the following color code: the base pairs for which the chemical shift variation of the imino group upon addition 
of the protein is ≥0.05 ppm are in red, between 0.03 and 0.05 ppm in orange and equal to 0.02 ppm in yellow. Mapping on the tRNALys3 3D structure (PDB 
code 1FIR) of the binding sites of the Vif protein and its domains: (C) Vif, (D) Vif (1–97), (E) Vif (95–192) at 2 equivalents and (F) Ncp7 at 3 equivalents.64 
The color code is the same as in B.
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Q
max
 reaches 23% (65% for tRNALys
3
) with a dissociation con-
stant 3-fold higher than the one observed for tRNALys
3
, sug-
gesting that Vif proteins interaction with C10 and total tRNA 
extract is mainly driven by electrostatic non-specific interactions.
Vif and NCp7 proteins share the same binding sites on 
tRNALys
3
Our fluorescence analyses showed that Vif and its domains 
bind TAR and tRNALys
3
, two RNAs suitable for NMR studies. 
All our attempts to obtain TAR/Vif or Vif domains complexes 
at concentrations required for recording NMR spectra (around 
10–40 µmol/l) were unsuccessful mainly due to massive precipi-
tation of the protein/RNA complexes, thus preventing any fur-
ther NMR studies. Fortunately, the situation was more favorable 
to investigate the binding of Vif and its domains to tRNALys
3
 by 
NMR chemical shift mapping. This method consists of labeling 
one of the partners of a complex with nitrogen 15 (tRNALys
3
 
in our case) and in monitoring the variation of chemical shifts 
upon binding with the non-labeled 
partner (Vif or its domains). Indeed, 
15N-labeled tRNALys
3
 was produced as 
previously described62 and the chemi-
cal shifts of its imino groups were used 
to monitor its interaction with Vif 
(Fig. 3A). The imino groups involved in 
the protein-binding site experience the 
largest variations of chemical shifts. For 
instance, the imino groups of U8, U12, 
G15, T54, and G70 undergo the larg-
est variation of chemical shift, between 
0.05 and 0.08 ppm upon Vif binding 
(Fig. S2). Our NMR data indicate that 
Vif is most strongly bound to the T-arm, 
the acceptor arm, the variable loop, and 
the D-arm of tRNALys
3
 (Fig. 3B). The 
NMR footprint more clearly appears 
when reported on the 3D structure of 
tRNALys
3
 (Fig. 3C). Thus, Vif presented 
a strong binding site located in the core 
of tRNALys
3
. Interestingly, Vif (1–97) 
(Fig. 3D) binds in the core of tRNALys
3
 
at the junction between the T, accep-
tor and D arms. Vif (95–192) showed a 
more dispersed interaction but was still 
able to bind tRNALys
3
 T- and D-arms 
(Fig. 3E). Unfortunately, we were not 
able to examine Vif (1–150) binding 
to tRNALys
3
 due to the poor solubility 
of this protein. Interestingly, the NMR 
chemical shift mapping of Vif bound 
to tRNALys
3
 was almost identical with 
that of the one determined for NCp764 
(Fig. 3F), suggesting that these two 
proteins share the same binding sites on 
tRNALys
3
. Taken together, these results 
suggest that the interaction with the 
T-arm of tRNALys
3
 is dependent on the 
CTD of Vif while the interaction in the core of tRNALys
3
 at 
the junction of the accepetor, T and D arms occurs through its 
NTD.
The RNA chaperone activity of Vif is driven by its 
C-terminal domain
In order to identify the domain of Vif involved in RNA chap-
erone activity, we compared the capacity of full-length Vif and its 
domains (1) to modulate HIV-1 RNA dimerization (Fig. 4) and 
(2) to activate the annealing of two complementary oligodeoxy-
nucleotides (TAR(+)/TAR(-) assay) in vitro (Fig. 5).
HIV-1 RNA dimerization assay
HIV-1 RNA can form two different types of dimers in vitro, 
termed loose and tight dimers depending on their thermal stabil-
ity that are correlated with the process of viral maturation after 
particle budding (for a review see ref. 65). Using an RNA frag-
ment encompassing the first 615 nucleotides of HIV-1 genomic 
RNA, RNA dimerization was analyzed under two different 
Figure  4. hIV-1 RNA dimerization induced by Vif and its domains. hIV RNA 1–615 was allowed to 
dimerize in the presence of increasing concentration of Vif, Vif (95–192), Vif (1–150), and Vif (1–97) 
(0.25, 0.5, 0.75 and 1 µM), and run on a 0.8% agarose gel in native (A), or semi-denaturing (B) con-
ditions after protein removal. Lanes D and M correspond to control incubation of RNA in dimeric 
(D) or monomeric (M) buffers (see Materials and Methods for composition). Monomeric RNA and 
RNA/RNA complexes (dimers and multimers) were visualized and quantified using a FLA 5000 (Fuji). 
Quantitation is indicated under each panel and corresponds to the percentage of RNA/RNA anneal-
ing complex (dimer+multimer/ dimer+multimer+monomer).
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electrophoresis conditions: (1) native conditions under which 
both loose and tight dimers are stable (Fig. 4A) and (2) semi-
denaturing conditions in which only tight dimers are stable 
(Fig. 4B).52 Vif and Vif (95–192), both stimulated RNA dimer-
ization in a concentration dependent manner (Fig. 4A), with a 
dimerization yield of 70% and 80% at 1 µM Vif protein, respec-
tively. This Vif-induced RNA dimer corresponds to tight dimer, 
as it is still observed under semi-denaturing conditions (Fig. 4B). 
Interestingly, these two Vif proteins were also able to induce the 
formation of multimers of RNAs, as previously observed66,67 
(Fig. 4B). However, while increasing concentration of Vif 
(1–150) and Vif (1–97) progressively increased the dimerization 
yield from 13–15 to 40–45% in native conditions (Fig. 4A), 
RNA dimers only marginally increased under semi-denaturing 
conditions (Fig. 4B). Surprisingly, a partial loss of RNA dimer 
signal was reproducibly observed for Vif (1–150) and Vif (1–97) 
(Fig. 4A and B). This is likely due to a higher degree of RNA 
aggregation of these two truncated forms, as previously observed 
for Pr55Gag protein.68 These results suggest that Vif (1–97) and 
Vif (1–150) were mainly able to induce the formation of loose 
dimers. Thus, Vif and Vif (95–192) mimic the NCp7-induced 
RNA dimerization activity suggesting that the RNA chaperone 
activity of Vif is partially mediated by its CTD encompassing 
Cul5 and EloC/B binding motifs as well as the PPLP sequence, 
and that this CTD is important, at least in vitro, to avoid the 
aggregation of the proteins.
TAR(+)/TAR(–) annealing assay
The annealing of complementary TAR sequences is essen-
tial to achieve (–) strand strong-stop DNA transfer, and among 
the various standard RNA chaperoning assays, the annealing 
of a TAR oligodeoxynucleotide (TAR+) to its complementary 
sequence (TAR-) has been used in many occasions.48,54 To iden-
tify and confirm the potential Vif domain(s) involved in RNA 
chaperone activity, we compared at a define time point the ability 
of Vif and its domains to promote the annealing of two comple-
mentary TAR DNA sequences with that of NCp7, NC (12–53) 
(peptide 12–53 of NCp7) and Tat, two other RNA chaperone 
proteins. In the absence of protein, TAR(+)/TAR(–) annealing 
occurred at 65 °C in high salt conditions in the positive control 
(Fig. 5, lanes 1). No TAR(+)/TAR(–) annealing was observed at 
37 °C in the negative control (Fig. 5, lane 2). Incubation with 
NCp7 or Tat at 37 °C for 5 min favored TAR(+)/TAR(–) anneal-
ing with an observed DNA complex yield at the highest protein 
concentration of 88 and 62%, respectively (Fig. 5, lanes 7 to 
14). Interestingly, in presence of Vif, TAR(+)/TAR(–) anneal-
ing was also observed with a complex yield (89%) very similar 
to the one observed for NCp7 (Fig. 5, lanes 3–6), suggesting 
that Vif was as efficient as NC in TAR(+)/TAR(–) annealing 
activity. As expected from previous studies,48,54,69 the NC (12–53) 
peptide was found to be poorly active in TAR-annealing activity 
and other RNA chaperone assays. Indeed, 71% of TAR annealed 
complex was obtained at 200 nM NC (12–53) (Fig. 5, lanes 
15–18), whereas 20 times less Vif protein was necessary to obtain 
this percentage after 5 min reaction (Fig. 5, lane 5). Surprisingly, 
when we analyzed the truncated domains of Vif, we showed that 
all of them were able to stimulate TAR(–)/TAR(+) annealing but 
at different level compared with Vif (Fig. 5, lanes 19–30). While 
Vif (1–150) and Vif (1–97) gave a maximum of 65 and 58% of 
annealed complex, respectively, at the highest Vif concentration, 
Vif (95–192) was able to anneal 90% of TAR DNA (Fig. 5, lanes 
19–22), a percentage close to the one observed for wild-type Vif.
Figure 5. stimulation of hIV-1 TAR(+)/TAR(-) DNA annealing by Vif and its domains. TAR(+) and 32P-labeled TAR(-) DNA oligonucleotides were co-incu-
bated in the presence of increasing concentrations of Ncp7 (wild-type and fragment 12–53), Tat, and Vif (full-length and domains). The protein con-
centrations were 2.75, 5.50, 11, and 22 nM except for Nc (12–53) for which the concentrations were 25, 50, 100 and 200 nM. In the absence of protein, 
double-stranded TAR DNA was formed upon incubation at 65 °c for 30 min (ct+, lanes 1) but not at 37 °c (ct-, lanes 2). TAR(+)/TAR(-) was annealed at 37 
°c for 5 min with hIV-1 Ncp7 (protein/nt molar ratios of 1/40, 1/20, 1/10 and 1/5) (lanes 11–14), Tat (lanes 7–10), Vif (lanes 3–6), Nc (12–53) (lanes 15–18), Vif 
(95–192) (lanes 19–22), Vif (1–150) (lanes 23–26), and Vif (1–97) (lanes 27–30). TAR(+)/TAR(-) complexes were visualized and quantified using a FLA 5000 
(Fuji). Quantitation is indicated under the panel and corresponds to the percentage of TAR(+)/TAR(-) DNA complexes (TAR(+)/TAR(-) / TAR(+)/TAR(-) + TAR 
DNA alone) after 5 min reaction.
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Taken together, these two assays indicate that Vif possesses 
nucleic acid chaperone activity that is driven in part, but not only, 
by its C-terminal unstructured domain.
Discussion
In this study, we investigated the RNA binding and chap-
eroning activities of HIV-1 Vif. First, by using CD and NMR 
spectroscopies, we showed that the NTD of Vif, encompassing 
residues 1–97, is the most structured domain in solution, whereas 
the CTD (95–192) remains mainly unfolded either alone or 
within the full-length Vif. Therefore, even if we cannot definitely 
exclude subtle differences in the secondary structure of these 
domains alone or within the full-length Vif, our analysis suggests 
that their secondary structure contents are similar in these two 
states. Second, we showed that the NTD of Vif binds with high 
affinity to RNAs that were previously described as Vif preferen-
tial binding sites, such as TAR at the 5′-end of the HIV-1 genomic 
RNA and gag coding region.46,50 This is in agreement with a pre-
vious study showing that a peptide from amino acids 1 to 64 
of HIV-1 Vif possesses a strong RNA binding activity.26 Indeed, 
highly conserved hydrophobic residues such as W11, Y30, and 
Y40 are present in the N-terminus of Vif from several primate 
lentivirus strains, and their mutation significantly decreased the 
binding of Vif to RNAs.26 Unexpectedly, we showed that the 
CTD of Vif is also able to bind these RNAs with high affinity. 
Notably, Vif proteins from several strains of HIV-1, HIV-2, and 
SIV are composed of heterogeneous sequences notably in their 
CTD, yet their unfolded characteristic is conserved and they can 
functionally complement each other.70,71 Moreover, while the 
sequences of Vif from HIV-1, HIV-2, and SIV strains are highly 
divergent in the CTD, a high number of arginines and lysines in 
the CTD of Vif (10–17 according to the strain), and thus a con-
servation of a significant net positive charge is still encountered. 
Therefore, the overall basic and unfolded character of the CTD 
of Vif in primate lentiviruses is conserved. This feature prob-
ably contributes to the RNA binding and chaperoning activities 
of Vif as such intrinsically disordered domains are proposed to 
support chaperone activity.72-74 Interestingly, we showed that the 
CTD of Vif facilitates nucleic acid annealing as demonstrated 
in our HIV-1 RNA dimerization and TAR(+)/TAR(–) anneal-
ing assays. At this point, comparing NCp7 and Vif seems very 
interesting. NCp7 is the most efficient RNA chaperone protein 
encountered in HIV,53 and our results show that the annealing 
activity of Vif is as efficient as NCp7 and slightly better than 
the one determined for Tat. The N-terminal basic residues of 
NCp7 are responsible for some of the RNA chaperone activity, 
like annealing and aggregation of nucleic acids, whereas the zinc-
fingers are responsible for the specific destabilization of nucleic 
acids.53 The efficiency of the NCp7 NTD to promote annealing 
of complementary RNA is essentially electrostatic, due to charge 
complementarities between nucleic acid backbone and positively 
charged residues,18,61 and is exemplified in our experiments when 
we compared the annealing activity of NCp7 and NC (12–53) 
lacking the N-terminal part (Fig. 5). Actually, NC (12–53) has 
lost most of its annealing activity (20 times less efficient than 
NCp7 and Vif). Interestingly, the basic and unfolded CTD of 
Vif clearly drives nucleic acids annealing activity of the protein, 
suggesting that the RNA chaperone activity of Vif and NCp7 is 
partially driven by their basic unfolded domains, at least regard-
ing their annealing activities. More generally, many proteins do 
not have well-ordered structures in their functional parts, repre-
senting hybrids containing both ordered and disordered regions. 
Coherently, the highly structured Vif NTD is responsible for a 
specific interaction with nucleic acids, similarly to NCp7 that 
specifically binds RNA via its zinc-knuckles.75 Contrary to what 
was observed with NCp7, whether zinc binding could enhance 
the RNA annealing activity of Vif is still a matter of debate. First, 
it has been shown in vitro that full-length Vif and short Vif pep-
tides corresponding to the HCCH motif (amino acids 101–142) 
are capable to bind zinc with high specificity but zinc bind-
ing induces conformational change that leads to the formation 
of large aggregates.76 Second, a peptide containing the HCCH 
motif is not able to bind nucleic acids, independently on the 
presence of zinc (JC Paillart, unpublished data), suggesting that 
the HCCH and SOCS-box domains do not participate to RNA 
binding. Altogether, it seems that the NTD of Vif specifically 
binds Vif cognate RNAs, whereas the CTD possesses the ability 
to bind RNAs with a strong RNA annealing activity. Moreover, 
in good agreement with previous in vitro analyses,12,46,47,50 these 
data suggest that the C-terminal His-tag used to purify Vif did 
not have a significant impact on the functional properties of Vif 
structural domains.
For the first time, we showed, that Vif can directly bind 
tRNALys
3
, the primer of HIV-1 reverse transcription. Indeed, 
the NTD has a definite and specific binding site to the inside 
of the L-shape of tRNALys
3,
 whereas the fingerprint with the 
CTD is more diffused, most likely indicating a less specific bind-
ing. Moreover, the CTD is responsible for the interaction with 
the T-arm of tRNALys
3,
 whereas the NTD of Vif is not able to 
bind this arm that needs to be annealed to the PBS to promote 
efficient initiation of reverse transcription. Interestingly, NMR 
chemical shift mapping demonstrates that Vif and NCp7 share 
the same binding sites on tRNALys
3
. We previously showed in 
vitro that Vif promotes hybridization between viral RNA and 
tRNALys
3
 generating a functional complex, but that the initial 
steps of reverse transcription (addition of the first nucleotides) are 
inhibited by Vif.52 In presence of NCp7, Vif was shown to inhibit 
NCp7-assisted hybridization of tRNALys
3
 to viral RNA.52 Our 
results are not surprising regarding the fact that Vif and NCp7 
share the same binding site on tRNALys
3
 (Fig. 3), thus leading 
to the conclusion that Vif and NCp7 are probably in competi-
tion for the same binding sites therefore inhibiting premature 
reverse transcription77,78 during the early steps of viral assembly. 
It is more likely that the inhibiting effect of Vif would be reduced 
during and/or after virion assembly since less than 100 Vif are 
packaged into viral particles.13,79,80 After this step, Pr55Gag is pro-
cessed by viral protease to give matured NCp7 whose concentra-
tion exceeds rapidly that of Vif, thus preventing Vif inhibition on 
reverse transcription.
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In summary, we showed that HIV-1 Vif is a complex RNA 
binding protein involving both its structured NTD, through 
conserved hydrophobic residues, and its unfolded CTD through 
non-specific electrostatic interactions. Interestingly, this lat-
ter domain seems responsible for most of the RNA chaperone 
activity of Vif, and this feature is strongly correlated with the 
unfolded nature of the CTD. Although we observed that Vif and 
NCp7 interact with common tRNALys
3
 motifs, their exact role 
during the initial steps of reverse transcription will need further 
investigation.
Materials and Methods
Expression and purification of Vif and its domains
Vif expression vectors were constructed by PCR and clon-
ing into the pET-52b(+) vector (Novagen). First, pD10Vif 
expression vector (Vif HXB2) was PCR-amplified with the 
corresponding forward (F) and reverse (R) primers: (F Vif) 
5′GGTCCATGG  AAAACAGATG GCAG3′ and (R Vif) 
5′GGTGAGCTCG TGTCCATTCA TTGTG3′; (R Vif 1–97) 
5′GGTGAGCTCT TGTGTGCTAT ATCTCTT3′; (R Vif1–
150) 5′GGTGAGCTCT AGTGCCAAGT ATTGTAG3′ giving 
rise to vectors expressing full-length Vif, domains 1–97 and 1–150 
of Vif, respectively. Primers (F Vif95–192) 5′GGTCCATGG 
TAGACCCTGA ACTAGCAGAC3′ and (R Vif 95–192) 
5′CACAATGAAT GGACACGAGC TC3′ were used to gener-
ate a plasmid expressing domain 95–192 of Vif. Forward primers 
contain a NcoI restriction site (underlined) while reverse primers 
contain a SacI restriction site (underlined). After purification of 
the PCR products (Nucleospin PCR clean-up, Macherey Nagel), 
DNA fragments were digested with NcoI and SacI, and cloned 
into pET-52b(+) vector previously digested with the same restric-
tion enzymes. The sequence of all constructs, pET52b(+) Vif, Vif 
(1–97), Vif (1–150) and Vif (95–192), was confirmed by DNA 
sequencing (GATC Biotech).
Escherichia coli BL21(DE3) competent cells were transformed 
with plasmids coding for Vif, Vif (1–97), Vif (1–150), and Vif 
(95–192). Expression of Vif and its domains were induced by 
addition of 1 mM IPTG in exponential phase of cultures (absor-
bance at 600 nm around 0.6). After 3 h of induction at 37 °C, 
bacteria were harvested by centrifugation at 6000 g during 15 
min, lysed in denaturing lysis buffer (6 M guanidine hydro-
chloride, 100 mM sodium phosphate, 10 mM TRIS-HCl pH 
8) at room temperature and stirred overnight. Cellular debris 
was separated by centrifugation at 27 000 g during 30 min at 
4 °C and the cleared lysate was loaded onto a Ni-NTA agarose 
column. The column was washed with lysis buffer and elution 
was performed by decreasing the pH from 6.5 to 4.5. Fractions 
containing Vif proteins were analyzed on 14% SDS–PAGE and 
pooled. Proteins were then renatured by slow dialysis against 
buffers with decreasing guadinium chloride concentration, and 
finally against the following buffers: Vif (50 mM MOPS, 1 mM 
DTT, 50 mM NaCl, pH 6.5), Vif (1–97) (50 mM MOPS, 50 
mM NaCl pH 6.5), Vif (95–192) (50 mM MES pH 6.5, 9.6 mM 
NaCl, 0.4 mM KCl, 2 mM MgCl
2
, 2 mM CaCl
2
, 1 mM DTT), 
and Vif (1–150) (50 mM MOPS pH 6.5, 1 mM DTT, 50 mM 
NaCl). The same protocol was followed to produce 15N-labeled 
Vif (95–192) except that the LB media was changed for spectra 9 
(15N) media (Cambridge isotope laboratories or Cortecnet). The 
proteins were concentrated using Centriprep YM 3 (Millipore) 
up to 0.4 mg/mL and ultracentrifuged at 100 000 g for 30 min at 
4 °C before adding 10% glycerol. Vif proteins were then stored 
at 4 °C and immediately prior to use Vif, stock solutions were 
ultracentrifuged at 100 000 g for 30 min at 4 °C to eliminate 
aggregates in solution. For NMR studies, no glycerol was added.
Nucleic acids preparation
Plasmids pHXB2 corresponding to parts of gag were obtained 
as previously described.50 To express RNA fragments correspond-
ing to nucleotides 499–996 (RNA B) and 499–799 (Short RNA 
B) of HIV-1 genome, plasmids were linearized with PvuII and 
SalI, respectively, and then used as template for in vitro run off 
transcription with bacteriophage T7 RNA polymerase under 
conditions previously described.81 After 3 h at 37 °C, the reaction 
mixture was incubated for 1 h at 37 °C with RNase-free DNase 
I (Roche), and then extracted with phenol-chloroform. RNAs 
were then purified with FPLC (Pharmacia) using a TSK250/
G2000SW column (TOSOH Bioscience) in a buffer contain-
ing 200 mM sodium acetate (pH 6.5) and 1% (v/v) methanol as 
previously described,66 precipitated in ethanol and dissolved in 
Milli-Q water (Millipore) prior to use.
15N-labeled tRNALys
3
 was expressed in E. coli (JM101TR 
strain) from a recombinant plasmid and purified as previously 
described.62 The RNA oligonucleotide corresponding to the api-
cal part of the TAR hairpin (5′CGAGCCUGGG AGCUCG3′) 
was purchased from Microsynth or Dharmacon and puri-
fied using HPLC (ÄKTA design-Unicorn) system with a (PA-
100) anion exchange column (Dionex), and concentrated with 
Centricon ® (Millipore).
Dynamic light scattering (DLS)
Samples were prepared in their buffers, and final protein 
sample concentrations were determined after ultracentrifugation. 
Intensities of scattered light and correlation times were measured 
with a Zetasizer Nano S (Malvern). Measurements were per-
formed in a single 50 µl trUView cuvette (Biorad Laboratories), 
maintained at 20 °C. DLS fluctuations of the scattering inten-
sity due to Brownian motion were recorded at microsecond time 
intervals. An autocorrelation function was then derived, allowing 
determination of diffusion coefficients, D. Assimilating proteins 
in solution to spheres, diffusion coefficients were related to the 
hydrodynamic radius of the particles (R
h
) via the Stokes-Einstein 
equation:
D = kT / R
h
 6π µ
in which k is the Boltzmann constant, T the temperature (K), 
and µ the solvent viscosity. All experimental data were corrected 
for solvent viscosity (measured with a 3.5 ml micro-Ubbelohde 
capillary viscosimeter tube from Schott), and refractive index 
(measured with an Abbe’s refractometer). To analyze the oligo-
merization state of Vif and its functional domains, scattering 
data were then analyzed using DLS analysis software (Malvern).
Circular dichroism (CD)
www.landesbioscience.com RNA Biology 917
Vif protein samples were prepared anaerobically in 50 mM 
MOPS, 150 mM NaCl, pH 6.5. Far-UV CD spectra (190–250 
nm) were measured with a Jasco J-810 spectropolarimeter (Jasco 
Inc.). Samples were placed in rectangular quartz cuvettes of 2 
mm path length maintained at 20 °C. Spectra were acquired at 
50 nm/min with a time constant of 1 s and bandwidth equal to 1 
nm. Each spectrum represents the average of at least 15 successive 
baseline-corrected scans. The mean residue molar ellipticity was 
determined according to equation: [θ] = (θ•M
R
)/(10•λ•c)
where θ is the measured ellipticity in millidegrees, M
R
 is the 
mean residue mass, λ the optical path length and c, the protein 
concentration. Deconvolution of far-UV CD spectra and con-




Fluorescence measurements were recorded in quartz cells at 20 
± 0.2 °C on a Fluoromax-4 fluorometer (HORIBA Jobin-Yvon 
Inc.). The excitation wavelength was set at 295 nm for selective 
excitation of Trp residues. The emission wavelength was scanned 
from 310 to 500 nm. The integration time was 0.1 s, and the exci-
tation and emission bandwidths were 5 nm. Fluorescence titra-
tions were performed by adding increasing amounts of nucleic 
acid to 100 nM of protein in 30 mM Tris–HCl (pH 7.5), 200 
mM NaCl, and 10 mM MgCl
2
. Fluorescence intensities were 
then corrected for buffer fluorescence and dilution effect. To 
determine the binding parameters of Vif proteins to RNA frag-
ments, we measured the decrease of the fluorescence intensity, I, 
at a fixed concentration of protein in presence of increasing RNA 
concentrations. Fluorescence intensities were corrected for dilu-
tion and were fitted using the following equation:
where I
0
: Fluorescence intensity of protein without RNA; I: 
fluorescence intensity at a given concentration of RNA; I
∞
: fluo-
rescence intensity at the plateau of binding titration; n: num-
ber of RNA binding sites on the protein; L
t
: total concentration 
of RNA; N
t
: total concentration of protein. Confidence limits 
on the K
D
 were estimated by Monte-Carlo sampling using the 
MC-Fit program.82
NMR chemical shift mapping
NMR data were recorded at 20 °C on a Bruker Avance 
DRX600 spectrometer equipped with a TCI cryoprobe. 1D 1H 
NMR spectra were recorded using a watergate sequence for solvent 
suppression.83 512 scans were usually acquired. 1H-15N TROSY 
experiments84 were performed with 128 t1 increments and 2048 
t2 data points per increment. The t1 dimension was acquired with 
the echo-antiecho method. For Vif (1–97) at 40 μM and Vif 
(95–192) at 36 μM, 1 equivalent of tRNALys
3
 stock at 0.9 mM 
was directly added to the protein sample. For full-length Vif, the 
previous operating mix led to precipitation of the protein. So, the 
complex components were mixed diluted at a 1:1 ratio and were 
then concentrated in a Centriprep YM 3 (Millipore) to a final 
concentration of each species around 20 μM.
Chemical shift variations Δ(H,N) were derived from 1H and 
15N shift differences: Δ(H,N) = [(Δ15N W
N
)2 + (Δ1H W
H
)2]1/2, 






 is the chemical shift of the imino 
group in the complex and δ 
free
 is the chemical shift of the imino 
group when tRNALys
3
 is free in solution), W
H
 = 1 for the proton 
chemical shift variation and W
N
 = 1/6 for the nitrogen chemical 
shift variation.
RNA chaperone activity
DNA and RNA substrates
Oligodeoxynucleotides (ODNs) used for the TAR(+)/
TAR(–) DNA annealing assay corresponded to nucleotides 1–56 
of the HIV-1 RNA sequence (MAL isolate, Accession Number 
X04415.1) in the sense and antisense orientations, as previously 
described.48 TAR(+): 5′-GGTCTCTCTT GTTAGACCAG 
GTCGAGCCCG GGAGCTCTCT GGCTAGCAAG 
GAACCC-3′ and TAR(-): 5′-GGGTTCCTTG 
CTAGCCAGAG AGCTCCCGGG CTCGACCTGG 
TCTAACAAGA GAGAC-3′. RNA fragments used in the RNA 
dimerization assay corresponded to nts 1–615 of the HIV-1 MAL 
genomic RNA.
Proteins
HIV-1 NCp7 and NC (12–53) proteins were synthesized and 
purified as described.85 The HIV-1 Tat protein was synthesized 
as reported in ref. 48.
RNA dimerization assay
RNA dimerization was performed as described previously.52 
Briefly, 100 nM of unlabeled HIV-1 1–615 RNA fragment were 
diluted in 10 µl of water together with the corresponding labeled 
RNA (5,000 cpm, 3–5 nM). Samples were denatured for 2 min 
at 90 °C, and snap-cooled on ice for 2 min. Dimerization was 
initiated by addition of Vif proteins under conditions disfavor-
ing salt-induced RNA dimerization, or so called monomeric buf-
fer (50 mM sodium cacodylate pH 7.5, 50 mM NaCl, 0.1 mM 
MgCl
2
). When no protein was used to induce RNA dimeriza-
tion, high salt dimeric buffer was used (50 mM sodium cacodyl-
ate pH 7.5, 300 mM NaCl, 5 mM MgCl
2
). RNA samples were 
incubated 30 min at 37 °C, deproteinized, and resuspended in 
glycerol-containing loading buffer, split in two equal volumes 
and analyzed on a 0.8% agarose gel in native (Tris–Borate 0.5X, 
MgCl
2
 0.1 mM, run at 4 °C) or semi-denaturing (TBE 1X, run 
at 20 °C) electrophoresis conditions. Gels were fixed in 10% tri-
chloroacetic acid for 10 min and dried for 1 h under vacuum at 
room temperature. Radioactive bands corresponding to mono-
meric and dimeric species were visualized and quantified using 
a FLA 5000 (Fuji).
TAR(–)/TAR(+) DNA annealing assay
The DNA annealing assay was performed as described in.18,48 
Briefly, 0.03 pmol of the TAR(+) and 32P-TAR(–) ODNs were 
incubated in 10 µl of buffer A (20 mM TRIS-HCl pH 7.0, 30 
mM NaCl, 0.1 mM MgCl
2
, 5 mM DTT, and 10 µM ZnCl
2
) 
with increasing concentrations of Vif, NCp7 or Tat proteins, as 
indicated in legend of Figure 5. Reactions were performed at 37 
°C for 5 min except for the positive control that was incubated 
at 65 °C. To stop the reaction and remove the protein from the 
32P-ODN, 5 µl of a solution containing 20% glycerol, 20 mM 
EDTA pH 8.0, 2% SDS, 0.25% bromophenol blue, and 0.4 mg/
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ml calf liver tRNA were added. Samples were resolved by 8% 
native PAGE in 50 mM Tris–borate pH 8.3, 1 mM EDTA at 
4 °C. Subsequently, gels were fixed, autoradiographed, and the 
amounts of labeled single-stranded and double-stranded DNA 
were visualized and quantified using a FLA 5000 (Fuji).
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